Ingevity Q3 net loss $107.2M; sales down 16% YoY; affirms FY adjusted EBITDA guidance

Ingevity Corp

2024-Q3 EPS reported -$12.31 revenue$1,107,600,000

Net sales $376.9M, down 16% YoY, primarily due to Performance Chemicals repositioning.
Net loss $107.2M ($2.95 diluted EPS) includes $86.9M restructuring charges and $100M contract termination fees.
Adjusted EPS $1.10; adjusted EBITDA $106.4M (28.2% margin).
Full-year guidance: sales $1.40-$1.50B, adjusted EBITDA $350-$360M.
Operating cash flow $46.5M, free cash flow $28.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.